CytomX Therapeutics, Inc. (CTMX)
5.43
-0.04
(-0.73%)
USD |
NASDAQ |
Feb 20, 16:00
5.44
+0.01
(+0.18%)
After-Hours: 20:00
CytomX Therapeutics EPS Diluted (Quarterly) : -0.0862 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| REGENXBIO, Inc. | -1.198 |
| ACADIA Pharmaceuticals, Inc. | 0.4206 |
| Alnylam Pharmaceuticals, Inc. | 1.368 |
| Savara, Inc. | -0.1366 |
| BioMarin Pharmaceutical, Inc. | -0.1601 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -14.23M |
| Revenue (Quarterly) | 5.963M |
| Total Expenses (Quarterly) | 20.19M |
| Enterprise Value | 782.00M |
| Gross Profit Margin (Quarterly) | 97.75% |
| Profit Margin (Quarterly) | -238.6% |
| Earnings Yield | 7.70% |
| Operating Earnings Yield | 3.70% |
| Normalized Earnings Yield | 7.692 |